View Older Stories View More Recent Stories

Apr 22, 2025 04:40PM After-hours movers: Tesla, Oklo, Intuitive Surgical and more

Apr 22, 2025 04:20PM Bristol-Myers Squibb (BMY) Phase 3 ARISE Trial Evaluating Cobenfy as Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia Did Not Reach Threshold

Apr 22, 2025 07:20AM Cantor Fitzgerald Starts Bristol-Myers Squibb Co. (BMY) at Neutral

Apr 21, 2025 05:31PM Piper Sandler Starts Bristol-Myers Squibb Co. (BMY) at Overweight

Apr 21, 2025 06:35AM Goldman Sachs Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)

Apr 15, 2025 08:37AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

Apr 14, 2025 04:15PM Bristol-Myers Squibb (BMY) Provides Update on Phase 3 ODYSSEY-HCM Trial

Apr 11, 2025 03:49PM Bristol-Myers Squibb (BMY): FDA Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Apr 11, 2025 10:08AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $54 at UBS

Apr 9, 2025 09:19AM Pharma stocks slide after Trump signals tariffs on sector

Apr 8, 2025 03:39PM Bristol-Myers Squibb (BMY): FDA Approves Opdivo plus Yervoy as Treatment for Patients with Previously Untreated MSI-H or dMMR

Apr 8, 2025 01:27PM FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or DMMR Colorectal Cancer

Apr 8, 2025 05:09AM Goldman Sachs Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral

Apr 7, 2025 11:47AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

Apr 4, 2025 05:26AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

Apr 1, 2025 09:33AM Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks

Mar 31, 2025 08:10AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

Mar 28, 2025 08:55AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo

Mar 28, 2025 08:00AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo

Mar 27, 2025 09:44AM UBS Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)

Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma

Mar 15, 2025 04:00AM How could tariffs shake up the pharma sector?

Mar 14, 2025 06:59AM Bristol-Myers Squibb (BMY) Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi

Mar 10, 2025 10:17PM 2seventy bio (TSVT) Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

Mar 7, 2025 06:59AM Bristol-Myers Squibb (BMY) Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Mar 4, 2025 01:45AM Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Mar 3, 2025 04:16PM Bristol-Myers Squibb (BMY) Declares $0.62 Quarterly Dividend; 4.1% Yield

Feb 24, 2025 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Supplemental Biologics License Application for Opdivo Plus Yervoy

Feb 19, 2025 07:00AM Bristol-Myers Squibb (BMY) Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall

Feb 13, 2025 04:16PM Bristol-Myers Squibb (BMY) Reports Phase 3 RELATIVITY-098 Trial Did Not Meet Endpoint

Feb 10, 2025 06:59AM Bristol-Myers Squibb (BMY) Reports Positive Topline Results for Breyanzi

Feb 7, 2025 07:48AM Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman Sachs

Feb 6, 2025 07:00AM Bristol-Myers Squibb (BMY) Tops Q4 EPS by 20c; guides below consensus

Feb 5, 2025 11:05AM Bristol-Myers Squibb (BMY) call put ratio 9.2 calls to 1 put with a focus on May 16.50 calls into quarter results

Feb 5, 2025 05:12AM Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results

Feb 4, 2025 09:43AM Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Cantor Fitzgerald

Jan 31, 2025 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Jan 31, 2025 06:51AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Jan 29, 2025 09:12AM Cantor Fitzgerald provides update on Biotechnology stocks

Jan 13, 2025 11:14AM Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick

Jan 13, 2025 07:02AM Bristol-Myers Squibb (BMY) and ArsenalBio Achieve Milestone for AB-4000 Series

Jan 10, 2025 12:50PM Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year

Jan 8, 2025 10:12AM Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Truist Securities, Expects Launches to Drive Momentum

Jan 7, 2025 11:00AM TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'

Jan 2, 2025 12:39PM TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'

Dec 23, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Sotyktu

Dec 23, 2024 06:45AM Bristol-Myers Squibb (BMY) Receives EU Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Col

Dec 19, 2024 05:43AM JPMorgan Adds Bristol-Myers Squibb Co. (BMY) to Aanalyst Focus List

Dec 16, 2024 01:45PM Bristol-Myers Squibb (BMY) calls more active than puts on flat option IV

Dec 16, 2024 06:25AM Jefferies Upgrades Bristol-Myers Squibb Co. (BMY) to Buy

View More Recent Stories View Older Stories